Patients with melanoma who have received ipilimumab appear to be at an increased risk for a drug-hypersensitivity rash when treated with vemurafenib.
No takes yet. Share an insight, caveat, or question.
Harding et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: